PR Newswire Asia's news > Biotechnology

 < Previous page   |   Title only   |   Print    Next page > 
     
Acepodia Announces FDA Clearance of IND Application for ACE723, a Novel Dual-Payload Antibody-Drug Conjugate
FDA clearance enables initiation of a Phase 1 clinical trial and advances the first AD2C-generated candidate into clinical development ...
2026-09-04T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
DIMERIX SECURES A$34 MILLION NON-DILUTIVE FACILITY TO FUND KEY CLINICAL MILESTONES
Dimerix successfully enters into non-dilutive facility agreements to access A$34 million [1] with a syndicate of Australian and U.S. independent lenders, including the previously announced initial facility ...
2026-09-04T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
Novonesis to build next generation enzyme production facility in India
COPENHAGEN, Denmark , Sept. 4, 2026 /PRNewswire/ -- Novonesis will expand its facility in Patalganga and build one of the world's most advanced enzyme production facilities. The €600 million investment ...
2026-09-04T    Beverages   Biotechnology   Food/Beverages 
KANEKA UBIQUINOL™ WINS NUTRAINGREDIENTS ASIA INGREDIENT OF THE YEAR: HEALTHSPAN AWARD 2026
Award Shines Spotlight on Ubiquinol's Role in Mitochondrial Health and Mitoceutical Innovation in the Global Healthspan Movement ...
2026-09-04T    Banking/Financial Service   Biotechnology   Cosmetics & Personal Care   Health Care/Hospital 
Neurophet Appoints Leading U.S. Dementia Imaging Expert Dr. Ana M. Franceschi as Scientific Advisor
Dr. Franceschi currently serves as Director of Dementia Imaging and Director of Molecular Neuroimaging at Northwell Health, where she has led advances in brain MRI and PET imaging technologies Neurophet ...
2026-09-03T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
ClinHope Officially Establishes Hong Kong Branch to Strengthen Asia-Pacific Market Presence
TAIPEI , Sept. 3, 2026 /PRNewswire/ -- ClinHope today announced the official establishment of its Hong Kong branch. Following its operations in Taiwan and the United States, this marks another step in ...
2026-09-03T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Everest Medicines Announces China NMPA Approval of CARDAMYST® for the Conversion of Acute Symptomatic Episodes of Paroxysmal Supraventricular Tachycardia (PSVT) to Sinus Rhythm in Adults
SHANGHAI , Sept. 3, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, ...
2026-09-03T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
Insilico Medicine Included in the HKEX Tech 100 Index, Drawing Attention to Opportunities in AI Value Chain
CAMBRIDGE, Mass. , Sept. 3, 2026 /PRNewswire/ -- Insilico Medicine ("Insilico", HKEX: 3696), a clinical-stage drug discovery company powered by generative artificial intelligence (AI), announced ...
2026-09-03T    Biotechnology   Health Care/Hospital   Medical/Pharmaceuticals 
The Galien Foundation Announces the Nominees for the Inaugural 2026 Prix Galien Korea Awards
Historic First Edition Launches in Partnership with MK Media (Maekyung), Yozma Group Korea, the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPBMA), and KoreaBIO at the World Knowledge ...
2026-09-03T    Biotechnology   Health Care/Hospital   Medical Equipment   Medical/Pharmaceuticals 
AAHRPP Accredits Five More Research Entities
21 more organizations earn reaccreditation ...
2026-09-03T    Biotechnology   Health Care/Hospital   Higher Education   Medical/Pharmaceuticals 
 < Previous page    Next page >

Mobile | Full
Forum rule | About Us | Contact Info | Terms & Conditions | Privacy Statment | Disclaimer | Site Map
Copyright (C) 2026 Suntek Computer Systems Limited. All rights reserved
Disclaimer : In the preparation of this website, 88iv endeavours to offer the most current, correct and clearly expressed information to the public. Nevertheless, inadvertent errors in information and in software may occur. In particular but without limiting anything here, 88iv disclaims any responsibility and accepts no liability (whether in tort, contract or otherwise) for any direct or indirect loss or damage arising from any inaccuracies, omissions or typographical errors that may be contained in this website. 88iv also does not warrant the accuracy, completeness, timeliness or fitness for purpose of the information contained in this website.